Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - ReShape Lifesciences Inc. | obln-20201231ex3214afb34.htm |
| EX-31.2 - EX-31.2 - ReShape Lifesciences Inc. | obln-20201231ex31205b8fa.htm |
| EX-31.1 - EX-31.1 - ReShape Lifesciences Inc. | obln-20201231ex311ed3e95.htm |
| EX-23.2 - EX-23.2 - ReShape Lifesciences Inc. | obln-20201231ex232b6bfdc.htm |
| EX-21.1 - EX-21.1 - ReShape Lifesciences Inc. | obln-20201231ex211ca79b3.htm |
| EX-10.34 - EX-10.34 - ReShape Lifesciences Inc. | obln-20201231ex103470642.htm |
| EX-10.32 - EX-10.32 - ReShape Lifesciences Inc. | obln-20201231ex1032e67a2.htm |
| 10-K - 10-K - ReShape Lifesciences Inc. | obln-20201231x10k.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
Obalon Therapeutics, Inc.
Carlsbad, California
We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-213988, 333-218482, 333-224864, 333-232759, 333-235876, and 333-236062), Form S-3 (Nos. 333-221264 and 333-227160), and Form S-1 (Nos. 333-229142, 333-232276, and 333-236327) of Obalon Therapeutics, Inc. (“Company”) of our report dated March 12, 2021, relating to the consolidated financial statements, which appears in this Form 10-K.
/s/ BDO USA, LLP
Costa Mesa, California
March 12, 2021